Literature DB >> 17257682

Prevalence of mutations leading to complete C6 deficiency (C6Q0) in the Western Cape, South Africa and detection of novel mutations leading to C6Q0 in an Irish family.

Kelly L Parham1, Andrew Roberts, Andrew Thomas, Reinhard Würzner, Howard E Henderson, Paul C Potter, B Paul Morgan, Ann Orren.   

Abstract

Complement component C6 is one of five terminal complement components incorporated into the membrane attack complex. Complete deficiency of C6 (C6Q0) leads to an increased susceptibility to Neisseria meningitidis infections, and affected individuals typically present with recurrent meningococcal disease. There is a relatively high prevalence of C6Q0 in the Western Cape, South Africa and three frameshift mutations have previously been described to be responsible for C6Q0 in this area-879delG, 1195delC, and 1936delG (current nomenclature). We have now genotyped a further nine genetically independent individuals with C6Q0, confirming previous reports that the most common defect in the Western Cape is 879delG. Moreover, we report the first identification of the 878delA mutation within the Western Cape, which has previously only been reported in individuals of African descent living in the United States or Europe. We also investigated the genotype of an Irish C6Q0 individual and her sibling, and report two previously undescribed mutations. One mutation alters a tyrosine codon to a stop codon within exon 10. The second mutation is within the 5' donor splice site of intron 3, and would, in all probability, disrupt splicing. These two mutations were shown to segregate independently. We also discuss the nomenclature for reporting C6 and C7 gene mutations, as the current nomenclature does not follow the recognised guidelines.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17257682     DOI: 10.1016/j.molimm.2006.11.022

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  8 in total

1.  Complete deficiency of the sixth complement component (C6Q0), susceptibility to Neisseria meningitidis infections and analysis of the frequencies of C6Q0 gene defects in South Africans.

Authors:  A Orren; E P Owen; H E Henderson; L van der Merwe; F Leisegang; C Stassen; P C Potter
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

Review 2.  Disease-causing mutations in genes of the complement system.

Authors:  Søren E Degn; Jens C Jensenius; Steffen Thiel
Journal:  Am J Hum Genet       Date:  2011-06-10       Impact factor: 11.025

3.  Complement factor 5 (C5) p.A252T mutation is prevalent in, but not restricted to, sub-Saharan Africa: implications for the susceptibility to meningococcal disease.

Authors:  C Franco-Jarava; D Comas; A Orren; M Hernández-González; R Colobran
Journal:  Clin Exp Immunol       Date:  2017-04-20       Impact factor: 4.330

Review 4.  Infections of people with complement deficiencies and patients who have undergone splenectomy.

Authors:  Sanjay Ram; Lisa A Lewis; Peter A Rice
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

5.  Identification of a novel mutation in the C6 gene of a Han Chinese C6SD child with meningococcal disease.

Authors:  Ai-Qian Zhang; Yu-Xing Liu; Jie-Yuan Jin; Chen-Yu Wang; Liang-Liang Fan; Da-Bao Xu
Journal:  Exp Ther Med       Date:  2021-03-19       Impact factor: 2.447

6.  Novel pathogenic mutations identified in the first Chinese pedigree of complete C6 deficiency.

Authors:  Philip H Li; William Wy Wong; Evelyn Ny Leung; Chak-Sing Lau; Elaine Au
Journal:  Clin Transl Immunology       Date:  2020-07-08

Review 7.  Mechanisms in Neisseria meningitidis for resistance against complement-mediated killing.

Authors:  Elisabeth Kugelberg; Bridget Gollan; Christoph M Tang
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

Review 8.  Human genetics of meningococcal infections.

Authors:  Stephanie Hodeib; Jethro A Herberg; Michael Levin; Vanessa Sancho-Shimizu
Journal:  Hum Genet       Date:  2020-02-17       Impact factor: 4.132

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.